Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

Phase 1

Completed

Conditions: Adult Solid Neoplasm
BRCA1 Mutation Carrier
BRCA2 Mutation Carrier
Hereditary Breast and Ovarian Cancer Syndrome

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Pharmacological Study
Drug: Veliparib

First Posted Date: 2007-09-26

Last Posted Date: 2015-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 107

Registration Number: NCT00535119

Locations: 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 4 locations

Addressing Emotional and Cognitive Factors in Behavioral Weight Loss Treatment

Not Applicable

Completed

Conditions: Obesity
Overweight

Interventions: Behavioral: Affective and Cognitive Skills Training

First Posted Date: 2007-09-21

Last Posted Date: 2018-03-14

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 21

Registration Number: NCT00533052

Locations: 🇺🇸
The Miriam Hospital, Providence, Rhode Island, United States

The Effect of Dietary Sitosterol on Blood Sugar and Cholesterol

Not Applicable

Completed

Conditions: Sitosterolemia

First Posted Date: 2007-09-18

Last Posted Date: 2018-05-21

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 14

Registration Number: NCT00531128

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
University of Maryland Amish Research, Lancaster, Pennsylvania, United States

Effects of Recombinant Human Glutamic Acid Decarboxylase on the Progression of Type 1 Diabetes in New Onset Subjects

Phase 2

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: GAD-Alum and Aluminum hydroxide
Drug: GAD-Alum
Drug: Aluminum hydroxide

First Posted Date: 2007-09-14

Last Posted Date: 2020-05-07

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 145

Registration Number: NCT00529399

Locations: 🇺🇸
Childrens Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸
University of California-San Francisco, San Francisco, California, United States

and more 12 locations

AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer

Phase 2

Completed

Conditions: Malignant Pleural Effusion
Extensive Stage Small Cell Lung Cancer
Recurrent Small Cell Lung Cancer
Lung Metastases

Interventions: Drug: saracatinib

First Posted Date: 2007-09-12

Last Posted Date: 2017-12-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 23

Registration Number: NCT00528645

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2

Terminated

Conditions: Adenocarcinoma of the Prostate
Stage IV Prostate Cancer

Interventions: Drug: cediranib maleate
Drug: docetaxel
Drug: prednisone
Other: laboratory biomarker analysis

First Posted Date: 2007-09-10

Last Posted Date: 2018-08-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 57

Registration Number: NCT00527124

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Wayne State University, Detroit, Michigan, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

Evaluation of Albuminuria HIV-Infected Patients

Completed

Conditions: Proteinuria
HIV-Associated Collapsing Glomerulopathy
HIV-Associated Focal Segmental Glomerulosclerosis
Albuminuria
Renal Tubular Toxicity

First Posted Date: 2007-09-05

Last Posted Date: 2018-04-05

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 252

Registration Number: NCT00524992

Locations: 🇺🇸
Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

HIV Antiretroviral Drugs and Metabolism

Not Applicable

Conditions: HIV Infections

Interventions: Drug: ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz

First Posted Date: 2007-09-05

Last Posted Date: 2011-03-16

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 60

Registration Number: NCT00525239

Locations: 🇺🇸
Department of Veterans Affairs Medical Center, San Francisco, California, United States

Tenofovir Alone Versus Tenofovir With Emtricitabine to Treat Chronic Hepatitis B

Phase 2

Terminated

Conditions: Hepatitis B

Interventions: Drug: Tenofovir
Drug: Tenofovir & Emtricitabine

First Posted Date: 2007-09-03

Last Posted Date: 2019-06-05

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 35

Registration Number: NCT00524173

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Effects of Diet Changes on Metabolism

Completed

Conditions: Obesity

First Posted Date: 2007-08-31

Last Posted Date: 2025-05-28

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 203

Registration Number: NCT00523627

Locations: 🇺🇸
NIDDK, Phoenix, Phoenix, Arizona, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy